Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors

por Cives, M, Kunz, P L, Morse, B, Coppola, D, Schell, M J, Campos, T, Nguyen, P T, Nandoskar, P, Khandelwal, V, Strosberg, J R
Publicado en Endocr Relat Cancer (2014)

Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors

por Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P.L., Kulke, M.H., Jacene, H., Bushnell, D., O'Dorisio, T.M., Baum, R.P., Kulkarni, H.R., Caplin, M., Lebtahi, R., Hobday, T., Delpassand, E., Van Cutsem, E., Benson, A., Srirajaskanthan, R., Pavel, M., Mora, J., Berlin, J., Grande, E., Reed, N., Seregni, E., Öberg, K., Sierra, M. Lopera, Santoro, P., Thevenet, T., Erion, J.L., Ruszniewski, P., Kwekkeboom, D., Krenning, E.
Publicado en N Engl J Med (2017)